The efficacy of PI3Kγ and EGFR inhibitors on the suppression of the characteristics of cancer stem cells

Yanning Xu, Said M. Afify, Juan Du, Bingbing Liu, Ghmkin Hassan, Qing Wang, Hanbo Li, Yixin Liu, Xiaoying Fu, Zhengmao Zhu, Ling Chen, Masaharu Seno

Research output: Contribution to journalArticlepeer-review

Abstract

Cancer stem cells (CSCs) are capable of continuous proliferation, self-renewal and are proposed to play significant roles in oncogenesis, tumor growth, metastasis and cancer recurrence. We have established a model of CSCs that was originally developed from mouse induced pluripotent stem cells (miPSCs) by proposing miPSCs to the conditioned medium (CM) of cancer derived cells, which is a mimic of carcinoma microenvironment. Further research found that not only PI3K-Akt but also EGFR signaling pathway was activated during converting miPSCs into CSCs. In this study, we tried to observe both of PI3Kγ inhibitor Eganelisib and EGFR inhibitor Gefitinib antitumor effects on the models of CSCs derived from miPSCs (miPS-CSC) in vitro and in vivo. As the results, targeting these two pathways exhibited significant inhibition of cell proliferation, self-renewal, migration and invasion abilities in vitro. Both Eganelisib and Gefitinib showed antitumor effects in vivo while Eganelisib displayed more significant therapeutic efficacy and less side effects than Gefitinib on all miPS-CSC models. Thus, these data suggest that the inhibitiors of PI3K and EGFR, especially PI3Kγ, might be a promising therapeutic strategy against CSCs defeating cancer in the near future.

Original languageEnglish
Article number347
JournalScientific reports
Volume12
Issue number1
DOIs
Publication statusPublished - Dec 2022

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'The efficacy of PI3Kγ and EGFR inhibitors on the suppression of the characteristics of cancer stem cells'. Together they form a unique fingerprint.

Cite this